Music Icon Returns to the International Theater October 8, with A Very Barry Christmas Returning for Its Sixth Year This December

2027 Performance Dates On Sale Now

LAS VEGAS, Sept. 21, 2026 /PRNewswire/ -- The hits keep coming home. Westgate Las Vegas Resort & Casino announced a new slate of 2027 performance dates for music icon Barry Manilow's acclaimed lifetime residency, Manilow: Las Vegas – The Hits Come Home!, at the legendary International Theater.

The newly announced 2027 performances will take place February 18–20, February 25–27, March 25–27 and April 1–3, with tickets on sale now.

Before looking ahead to 2027, Manilow makes his highly anticipated return to the International Theater on Thursday, October 8, kicking off an exciting fall and holiday run at Westgate. Performances continue throughout October and November before the return of the fan-favorite A Very Barry Christmas, celebrating its sixth year this December with three festive weekends of performances.

The residency continues a milestone year for Manilow, who released his latest studio album, What A Time, in June.

A VERY BARRY CHRISTMAS RETURNS FOR ITS SIXTH YEAR

It's the most wonderful time of the year—with Barry Manilow.

The holidays will sparkle a little brighter as A Very Barry Christmas returns to the International Theater for its sixth year. The festive production will take the stage over three weekends—December 3–5, December 10–12 and December 17–19—bringing Manilow's signature showmanship and holiday spirit back to one of Las Vegas' most legendary stages.

The holiday performances cap a busy fall for Manilow at Westgate, with additional 2026 residency dates scheduled for October 8–10 and 15–17, and November 5–7 and 12–14.

A RECORD-BREAKING LAS VEGAS LEGACY

Today, he holds the record for the most performances at the historic theater, further cementing his place in Las Vegas entertainment history. In 2024, Manilow made history again when he signed the first-ever Lifetime Residency Contract with Westgate Las Vegas Resort & Casino.

Manilow: Las Vegas – The Hits Come Home! is a high-energy celebration of an extraordinary musical career, featuring beloved classics including "Mandy," "Copacabana," "Can't Smile Without You" and "I Write the Songs." Immersive visuals, lush arrangements and Manilow's signature storytelling come together in a production created for the legendary International Theater stage.

2027 PERFORMANCE DATES

February: 18–20, 25–27

March: 25–27

April: 1–3

Tickets for the newly announced 2027 performances are on sale now.

REMAINING 2026 PERFORMANCE DATES

October: 8–10, 15–17

November: 5–7, 12–14

A VERY BARRY CHRISTMAS

December: 3–5, 10–12, 17–19

Tickets for remaining 2026 performances are on sale now click here.

About Westgate Las Vegas Resort & Casino

Located just off the world-famous Las Vegas Strip, Westgate Las Vegas Resort & Casino is a legendary destination offering dynamic dining, world-class entertainment, and one of the most iconic stages in Las Vegas history. Originally opened as the International Hotel—where Elvis Presley performed his record-setting residency—and now Barry Manilow reigns supreme, the property continues to honor its storied legacy while delivering a modern resort experience.

Today, Westgate features an expansive collection of dining destinations including Edge Steakhouse, Benihana—the largest in the world, Fresco Italiano, Sid's Café, Viva Coffee & Espresso and the International Bar, alongside a full-service Serenity Spa & Salon, the renowned SuperBook—the largest Race & Sportsbook in Las Vegas, and a diverse lineup of entertainment spanning the legendary International Theater, intimate cabaret-style showrooms, and live music venues.

Recognized as a Top 10 Resort on Tripadvisor in Las Vegas, the resort is also home to a wide range of accommodations, from beautifully appointed guest rooms to signature themed suites and expansive Sky Villas, offering guests a truly distinctive stay rooted in comfort, style and unforgettable experiences.

For Westgate Las Vegas media inquiries:

Jeff Wagner – [email protected]

Celena Haas-Stacey – [email protected]

Michelle Loosbrock – [email protected]

SOURCE Westgate Las Vegas Resort & Casino

Share this article

Travel brand builds on its For Every Season of You campaign, putting Michigan's fall offerings on full display and inviting travelers to embrace the season

LANSING, Mich., Sept. 21, 2026 /PRNewswire/ -- As fall descends across Michigan's 19 million acres of forests, Pure Michigan is inspiring travelers to slow down, connect with loved ones, and embrace the season of life they find themselves in at the moment. The celebrated travel brand marks 20 years of impact with seasonal marketing initiatives honoring the campaign's legacy while ushering in fresh ideas that elevate Michigan's status as a top fall travel destination.

"There's nothing more Pure Michigan than fall," said Governor Whitmer. "Go anywhere in Michigan this year and you'll see why. Cooler temperatures bring brilliant autumn colors, cider mills buzz with activity, and Michiganders and visitors alike enjoy everything from corn mazes to pumpkin carving. Fall in Michigan is truly unmatched, and we invite everyone to get out and experience the beauty, traditions, and magic of the season."

Seasonal advertising efforts build upon Pure Michigan's current For Every Season of You campaign, which celebrates 20 years of the brand and highlights how, no matter what season of life you're in, there's always something that draws you back to Pure Michigan.

"There is an unmistakable magic to autumn in Pure Michigan," said Kelly Wolgamott, Vice President of Pure Michigan. "It's a season that invites us to pause, breathe in the crisp air, and reconnect with the people and places that matter most. Whether you're seeking vibrant fall colors, looking to savor the season's fresh agricultural bounty, or wanting a place that will deliver that quintessential fall experience, Pure Michigan is ready to welcome you."

This fall, Pure Michigan is highlighting its ultimate autumn attraction with its In Vivid Color spot. The ad mixes nostalgia with Michigan's iconic fall colors that continue to inspire travelers in every season of their lives. It will run on premium CTV placements such as Amazon Prime and Netflix, and in online video ads and social platforms.

Pure Michigan's fall campaign went live in August across print, OOH, streaming audio, digital, connected TV, social, and search. The campaign, utilizing brand and partner funding, showcases the beauty of Michigan's autumn at a national level including a partnership with National Geographic, and targets key audiences regionally in Chicago, Cincinnati, Cleveland, Columbus, Dayton, Fort Wayne, Green Bay, Indianapolis, Milwaukee, Minneapolis, South Bend, and Toledo, and locally in Alpena, Detroit, Flint, Grand Rapids, Lansing, Marquette, and Traverse City.

Michigan's brilliant fall colors are also on display in a full-page spread in Midwest Living's fall "The Color Issue" which is currently on newsstands.

Fall Flavors

Short's Brewing Company and Pure Michigan have once again teamed up to craft the Pure Michigan Fall IPA. The seasonal brew is made with all Michigan-sourced ingredients that celebrate the magnificence of autumn and the state's world-class craft brewing industry. The Pure Michigan Fall IPA is currently pouring in select bars and restaurants throughout the state, and is available at craft beer retailers statewide. Find one here.

Fall Color Inspiration

For fall travel planning, the interactive Fall Color Map allows Michigan visitors and residents to track the transitions as they unfold across the state's two peninsulas. Travelers can also stay up-to-date on peak colors by subscribing to the Pure Michigan Fall Color Report at michigan.org/enews.

For more fall trip inspiration, travelers are encouraged to order a free print copy of the 2026 Pure Michigan Fall/Winter Travel Guide, or download a digital, universally accessible format at michigan.org. This year's guide puts Michigan's woods and waters on full display, includes scenic leaf-peeping itineraries and other ways for travelers to immerse themselves in Michigan's kaleidoscope of fall colors.

About Pure Michigan

Pure Michigan® is the official travel and tourism arm of the state, operating under the Michigan Economic Development Corporation, focused on inspiring travel across the Great Lakes State. Celebrating its 20th anniversary in 2026, the brand is a global leader in destination marketing, driving billions in economic impact. Recently named to Fast Company's "Brands That Matter" list, Pure Michigan is recognized for its cultural influence and ability to connect travelers with the state's diverse offerings. Discover more at www.michigan.org and join the conversation on Facebook, Instagram, Pinterest, Threads, TikTok, X, and YouTube.

Media Contact:

Sierra Powers

FINN Partners on behalf of Pure Michigan

[email protected] 

SOURCE Pure Michigan

Share this article

The article explains how sellers can prioritize property condition while avoiding costly cosmetic projects that may not add value.

SCHERERVILLE, Ind., Sept. 21, 2026 /PRNewswire/ -- What should you not fix before selling your house? A HelloNation article featuring insights from Real Estate Expert Kim Odegard of Odegard Real Estate Team | eXp Realty provides the answer.

The article explains that getting a house ready to sell does not require fixing every visible flaw. Sellers may notice old paint, worn floors, dated fixtures, or rooms that could be improved. Good home sale preparation starts with identifying which problems could truly matter to buyers.

Cosmetic updates are among the first projects many sellers consider. New countertops, cabinets, flooring, and light fixtures can make a home appear newer. However, the article notes that these improvements can become expensive, while buyers may have different preferences for colors, materials, and designs.

Kitchen and bathroom renovations are examples of projects sellers may want to reconsider. A complete remodel can require a significant investment even when the existing features function properly. The article explains that a buyer may still prefer to make changes after purchasing the property.

Flooring requires similar consideration. Older carpet, scratched hardwood, or dated tile may stand out during a showing, but replacing flooring throughout a house can be costly. Buyers may also prefer another material, making a large flooring project less valuable to them.

The article distinguishes cosmetic concerns from necessary home repairs before selling. A loose railing, leaking pipe, broken window, or active water problem could affect the home's safety or function. These problems may also receive greater attention during a home inspection.

Electrical, plumbing, roofing, and heating concerns may deserve attention before improvements based mainly on style. The article notes that a pre-listing inspection can sometimes provide more information about a home's condition before buyers begin viewing it. This approach is not appropriate for every seller, but it may identify issues earlier in the process.

Local market conditions can also influence repair decisions. The article explains that buyers may be more accepting of older finishes when fewer homes are available. When buyers have more choices, condition and appearance may receive closer attention.

Price range and neighborhood expectations also matter. Buyers often compare a property with similar homes nearby. If older kitchens or bathrooms are common in the area, updating those spaces may not be as important as addressing functional concerns.

Time and cost are additional factors in home sale preparation. Even projects that appear simple can take longer because of materials, contractors, or unexpected complications. Delaying a sale for an improvement that a buyer might later replace may not make financial sense.

The article notes that smaller projects can still help a property look cared for. Touching up damaged paint or repairing a loose handle is different from completing a major renovation. Sellers can focus on obvious maintenance concerns without trying to make every part of the home look new.

Real Estate Expert Kim Odegard provides insights featured in the article's discussion of local buyer expectations and repair decisions. The article also explains that inspectors and contractors can provide additional information when physical problems require specialized evaluation.

Choosing the right home repairs before selling ultimately involves considering condition, cost, timing, and likely buyer expectations. The article explains that sellers do not need to create a perfect house. Understanding which issues matter and which cosmetic projects can wait may help sellers avoid unnecessary work before listing.

What Not to Fix Before Selling Your House features insights from Kim Odegard, Real Estate Expert of Schererville, Indiana, in HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative "edvertising" approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article

ROCHESTER, N.Y., Sept. 21, 2026 /PRNewswire/ -- Insurance adjusters often call within hours of a car accident, requesting recorded statements that sound routine but can sabotage injury claims. A new HelloNation article from Rochester attorney John Wright exposes the hidden traps in these conversations and reveals why thousands of New York drivers unknowingly damage their own cases by being "too cooperative."

"People think they're just being helpful when an adjuster calls," says Wright, who has represented hundreds of accident victims in Rochester. "But I've seen cases destroyed by a single sentence. Someone says 'I feel fine' right after the crash, then three days later they can't get out of bed, and the insurance company uses that recording to deny their claim."

The biggest mistake? Talking to the other driver's insurance company. "You have zero obligation to speak with them," Wright emphasizes. "But they'll call, sounding friendly and concerned, asking 'just a few quick questions.' Everything you say gets recorded, analyzed, and weaponized against you. I tell every client: politely decline and hang up."

Insurance apps pose a newer threat that many drivers don't recognize. Wright warns that uploading photos or drawing accident diagrams in these apps creates permanent records that can backfire. "I've seen cases where someone drew an arrow showing their car position, and the insurance company used it to argue the driver was at fault," he explains. "These apps feel casual, but they're evidence-gathering tools designed to minimize payouts."

New York's no-fault system covers basic medical costs and lost wages, but fault still matters for serious injuries and property damage claims. "People assume no-fault means they don't need to worry about what they say," Wright notes. "But if you have significant injuries, you'll need to prove fault to recover full damages. Statements made in the first 48 hours before you even know how badly you're hurt can torpedo that claim months later."

Wright's advice is simple: provide basic facts to your own insurer, date, time, location, parties involved, but nothing more without legal counsel. For the other driver's insurance? "Just say 'I'm not prepared to discuss the accident at this time' and end the call," he advises. "You're not being difficult. You're protecting your legal rights."

The article details specific questions adjusters use to trap victims, reveals what information drivers are legally required to provide, and explains when it's time to consult an attorney. For Rochester accident victims facing pressure from insurance companies, Wright's insights could mean the difference between a fair settlement and a denied claim.

Should I Give a Recorded Statement or Use Insurance Apps After a Crash in New York? features insights from John Wright, Legal Expert of Rochester, NY, in HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused digital publications and innovative "edvertising" approach, HelloNation delivers expert-driven, good-news content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities. HelloNation maintains partnerships with the U.S. Conference of Mayors and the United States First Responders Association.

SOURCE HelloNation

Share this article

SHERIDAN, Wyo., Sept. 21, 2026 /PRNewswire/ -- The global immunoassay market is projected to grow from USD 35.5 billion in 2026 to USD 47.5 billion by 2031, registering a CAGR of 6% during the forecast period (2026–2031), according to a new study by Wissen Research.

Growth is being driven by rising prevalence of infectious diseases, cancer, and chronic and autoimmune disorders, alongside growing demand for fast, sensitive, and reliable detection of biomarkers, antibodies, and hormones. Wider adoption of automated, high-throughput analyzers and continued advances in chemiluminescence, electrochemiluminescence, and multiplex immunoassay technologies are improving diagnostic accuracy while extending testing into decentralized and point-of-care settings.

Get a Free Sample of This Report to Explore Key Findings and Data

Where Immunoassay Testing Is Heading: Multiplexing and Digital Detection

The next phase of growth in immunoassay testing is being shaped by a shift from single-analyte testing toward multiplex and digital immunoassay platforms capable of detecting several biomarkers simultaneously from a single, minimal-volume sample. Recent advances include barcoded multiplex digital ELISA systems capable of detecting up to eight targets from less than 9 microliters of blood with sensitivity reaching the low-attomolar range — a level of precision that opens the door to broader use in oncology biomarker panels, immune profiling, and precision diagnostics.

At the same time, automation continues to reshape laboratory throughput. High-throughput analyzers such as Roche's cobas e 801 can process more than 300 immunochemistry tests per hour with automated reagent handling and quality control, while integrated platforms like Siemens Healthineers' Atellica Solution combine clinical chemistry and immunoassay testing on a single system. Alongside this, microfluidic and point-of-care immunoassay platforms are extending testing beyond centralized laboratories into hospitals, physician offices, and decentralized clinical settings, supported by continued advances in miniaturization and digital detection.

What's Fueling Growth in the Immunoassay Market

- Rising Disease Burden: Growing prevalence of infectious diseases, cancer, cardiovascular disease, and autoimmune disorders is driving demand for accurate, sensitive immunoassay-based testing.

- Laboratory Automation: Growing adoption of automated, high-throughput immunoassay analyzers is improving efficiency, reducing manual intervention, and accelerating diagnostic turnaround times.

- Expanding Biomarker Applications: Rising demand for early disease detection is broadening immunoassay use across oncology, cardiac testing, endocrine disorders, and infectious disease diagnostics.

- Detection Technology Advances: Progress in chemiluminescence, electrochemiluminescence, and fluorescence-based platforms is improving assay sensitivity and specificity.

- Point-of-Care Expansion: Growing demand for decentralized testing is driving adoption of rapid immunoassay platforms that support timely diagnosis outside centralized laboratories.

- Pharmaceutical and Biotech Research Demand: Increasing use of immunoassays in drug development, therapeutic drug monitoring, and clinical trials is supporting sustained market demand.

Challenges Facing the Immunoassay Market

Cost remains a persistent barrier to broader adoption. Advanced automated analyzers and ultrasensitive digital immunoassay platforms require substantial upfront investment, while ongoing reagent, consumable, calibration, and maintenance costs add to the total cost of testing — a burden that can be especially difficult for smaller laboratories and resource-constrained healthcare facilities to absorb.

Analytical consistency presents further challenges. Cross-reactivity, non-specific binding, matrix effects, and interference from heterophile antibodies can all affect result accuracy, and highly sensitive assays require careful control of background signal to avoid false positives. Variation in assay formats, reagents, and calibration standards across different manufacturers and platforms also makes it difficult to achieve consistent results across laboratories — a standardization gap that continues to limit interoperability across the industry.

Recent Strategic Developments in the Immunoassay Market

In March 2026, QuidelOrtho partnered with Lifotronic to expand its global immunoassay offering beyond its existing VITROS diagnostic system portfolio.

In February 2026, LubioScience and Mabtech entered into a strategic partnership to strengthen availability of ELISA, EYRAplex, ELISpot, and FluoroSpot immunoassay technologies for research and diagnostics customers in Switzerland.

In March 2025, Gentian Diagnostics launched the GCAL Calprotectin Immunoassay together with Beckman Coulter Diagnostics, expanding availability of the assay across Beckman Coulter's clinical chemistry platforms.

These moves reflect a market where established diagnostics companies continue to broaden assay menus and international distribution through partnerships, while smaller specialized players expand access to niche and research-focused immunoassay technologies.

Key Insights from Immunoassay Market Analysis

- ELISA (enzyme-linked immunosorbent assay) is expected to hold the largest share by technology in 2025, supported by its wide use across clinical laboratories, research institutions, and blood banks, along with broad availability of commercial kits and established laboratory infrastructure.

- Hospitals are expected to represent the largest end-user segment in 2025, driven by high diagnostic testing volumes and integrated laboratory platforms combining clinical chemistry and immunoassay testing.

- North America held the largest regional share in 2025, supported by advanced healthcare infrastructure and a strong installed base of automated immunoassay analyzers.

- Asia-Pacific is projected to register the highest CAGR during 2026–2030, driven by expanding healthcare infrastructure, rising diagnostic testing volumes, and growing adoption of laboratory automation across China and India.

Key Players in the Immunoassay Market

Leading companies in the immunoassay market are focused on innovation, strategic partnerships, and expansion of assay menus and analyzer platforms to strengthen their market position.

Regional Analysis and Growth Opportunities

North America leads the immunoassay market, supported by advanced healthcare infrastructure, a strong installed base of automated immunoassay analyzers, and the presence of leading diagnostics manufacturers. High diagnostic testing volumes and continued investment in laboratory automation reinforce the region's leading position.

Asia-Pacific is the fastest-growing region, propelled by expanding healthcare infrastructure, rising diagnostic testing volumes, and growing pharmaceutical and biotechnology activity across China, India, Japan, and South Korea. Investment in healthcare technology, expansion of domestic diagnostic manufacturing, and rising demand for decentralized testing are reinforcing regional growth, with China and India serving as the primary drivers of expansion.

Europe, Latin America, and the Middle East & Africa complete the report's regional coverage, with growth supported by expanding diagnostic laboratory networks and rising adoption of point-of-care immunoassay testing.

Get a Custom Briefing on This Market for Your Business

Wissen Research's healthcare technology analysts are available to walk through findings specific to your market, region, or competitive set.

Need Insights Specific to Your Business? Request a Customized Version of This Report: https://www.wissenresearch.com/request-customization/?report=immunoassay-market

Market Segmentation Snapshot

The global immunoassay market is segmented across product, technology, sample, application, end user, and region:

- By Product:

- Reagents & Kits (ELISA, CLIA, FIA, Rapid Test, ELISpot, Western Blot, Others)

- Analysers

- By Technology:

- Enzyme-Linked Immunosorbent Assay (ELISA)

- Chemiluminescent Immunoassay (CLIA)

- Fluorescent Immunoassay (FIA)

- Electrochemiluminescent Immunoassay (ECLIA)

- Rapid Tests

- Western Blotting

- ELISpot

- By Sample:

- Blood

- Saliva

- Urine

- Other Specimens

- By Application:

- Infectious Disease Testing

- Cardiac Markers

- Endocrine Testing

- Tumor Markers

- Allergy Testing

- Drug of Abuse Testing / Therapeutic Drug Monitoring

- Autoimmune Disease Testing

- Coagulation Testing

- Other Biomarkers

- By End User:

- Hospitals

- Commercial/Centralized Diagnostic Laboratories

- Physician Offices/Clinics

- Academic and Research Institutions

- Pharmaceutical and Biotechnology Companies

- Other (Veterinary, Environmental)

- By Region:

- North America

- Europe

- Asia-Pacific

- Latin America

- Middle East & Africa

Frequently Asked Questions

Q: What is the size of the immunoassay market?

A: The global immunoassay market is estimated at USD 35.5 billion in 2026 and is projected to reach USD 47.5 billion by 2031.

Q: What is the growth rate of the immunoassay market?

A: The immunoassay market is projected to grow at a CAGR of 6% between 2026 and 2031.

Q: Which end-user segment leads the immunoassay market? A: Hospitals are expected to represent the largest end-user segment in 2025, driven by high diagnostic testing volumes and integrated laboratory platforms.

Q: Which region leads the immunoassay market?

A: North America held the largest share of the immunoassay market in 2025, while Asia-Pacific is projected to register the highest CAGR through 2030.

Q: Who are the top players in the immunoassay market?

A: The top players in the immunoassay market include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Agilent Technologies, Siemens Healthineers, and Thermo Fisher Scientific Inc.

The loan repayment program — created in collaboration with Clasp, a national leader in retention-driven healthcare recruiting — positions AHN as an employer of choice for early-career CRNA talent

PITTSBURGH, Sept. 21, 2026 /PRNewswire/ -- Allegheny Health Network (AHN) today announced the launch of a new national recruitment and loan repayment program designed to strengthen the pipeline of Certified Registered Nurse Anesthetists (CRNAs) in Western Pennsylvania.

The workforce investment campaign aims to address the ongoing regional and national shortages in CRNAs by reducing financial barriers to education and attracting early-career CRNA talent. A CRNA is an advanced practice registered nurse who specializes in administering anesthesia and monitoring patients before, during, and after surgical procedures.

Without an adequate supply of CRNAs, health systems have trouble meeting patient access demands for surgical procedures, especially elective procedures. Operating rooms face delayed starts and extended turnaround times, and CRNAs themselves experience higher burnout rates.

Through a new collaboration with Clasp, a national leader in retention-driven healthcare recruiting, AHN will provide employer-sponsored student loan repayment for qualified nurse anesthesia students who commit to joining the organization full-time as a CRNA after graduation.

The collaboration with Clasp allows AHN to reach a much broader, national population of CRNA candidates.

Clasp, based in Boston, connects employers to healthcare students through its national retention-driven recruitment platform. By enabling health care systems to sponsor loan repayment tied to early job commitments, Clasp helps employers to secure job commitments while students are still in school, and gives students and early-career professionals access to guaranteed debt relief, deferring loan repayment until after they hit retention milestones.

AHN is Clasp's first Pennsylvania collaborator.

How it works for students:

- Employer Matching: Students apply through Clasp and match with participating hospitals or health networks (such as AHN) that need nurse anesthetists.

- Work Commitment: Students agree to a multi-year employment term with AHN, in exchange for a debt repayment commitment.

- Direct Payments: Once the student begins full-time employment, AHN makes regular monthly payments directly to the federal or private student loan servicer, through the Clasp platform.

- No Claw-backs: Employees keep every dollar contributed by the employer toward principal balance.

Loan repayment is distributed over the employee's first three years of employment through the Clasp platform.¹

The launch comes as healthcare organizations nationwide continue to face significant shortages of CRNAs and other advanced practice clinicians, with hospitals competing aggressively for a limited pool of hard-to-hire talent. By investing in future CRNAs before they enter the workforce, AHN is taking a proactive approach to building a strong talent pipeline while helping nurse anesthesia students transition from school into high-impact clinical careers.

"Healthcare systems across the country are exploring innovative ways to recruit and retain talented clinical professionals, and anesthesia is clearly a priority for most organizations," said Stacy Kittridge, VP, Human Resources Highmark and AHN. "Working with Clasp gives us the opportunity to engage CRNA students earlier in their training, help ease one of the biggest financial barriers of pursuing this career path, and build lasting relationships with clinicians who will be critical to AHN's future workforce."

Eligible CRNA students who are within two years of graduation may apply to the program, receive an employment commitment prior to graduation, and begin receiving student loan repayment once they join AHN full-time.

"Healthcare organizations are rethinking how they attract and retain hard-to-hire clinical talent in an increasingly competitive labor market," said Tess Michaels, CEO & Founder of Clasp. "Allegheny Health Network is leading the way by investing in nurse anesthesia students before they graduate, creating a pathway that helps reduce student debt while building a stronger, more resilient CRNA workforce for Western Pennsylvania."

The initiative supports AHN's broader workforce strategy focused on talent attraction, retention, pipeline development, and expanding access to meaningful healthcare careers throughout the region.

Nurse anesthesia students interested in launching their careers with Allegheny Health Network are encouraged to visit careers.ahn.org or learn more about the program at clasp.com/alleghenyhealthnetwork.

About Allegheny Health Network

Allegheny Health Network (AHN.org) is an integrated health care delivery system serving the greater Western Pennsylvania region. The network is composed of 16 hospitals, ambulatory surgery centers, Health + Wellness Pavilions, an employed physician organization, home- and community-based health services, a research institute, and a group purchasing organization. AHN provides patients with access to a complete spectrum of advanced medical services, including nationally recognized programs for primary and emergency care, cardiovascular disease, cancer care, orthopedic surgery, neurology and neurosurgery, women's health, diabetes and more. AHN employs approximately 27,000 people, has 3,000 physicians on its medical staff, and serves as a clinical campus for Drexel University College of Medicine, Lake Erie College of Osteopathic Medicine and Duquesne University Nasuti College of Osteopathic Medicine.

About Clasp

Clasp is a venture-backed fintech company helping employers build stronger talent pipelines through pre-recruitment and employer-sponsored student loan repayment. By aligning education financing with workforce demand, Clasp reduces risk for employers, schools, and students alike. Learn more at clasp.com.

¹ If qualified, selected, and employed full-time by Allegheny Health Network, AHN will pay up to $110,000 toward eligible, synced student loans via the Clasp platform in annual lump-sum installments: up to $20,000 after 12 months of employment, up to $30,000 after 24 months of employment, and up to $60,000 after 36 months of employment. Program is open to full-time team members only; program selection is not guaranteed and is determined by AHN, not Clasp. Individuals may be subject to income tax on some or all loan payments made on their behalf. See program terms at clasp.com/students.

SOURCE Allegheny Health Network

Share this article

DALLAS, Sept. 21, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, LLP continues the strategic growth of its Finance Practice with the addition of Shan A. Khan as a shareholder in its Dallas office.

Khan, who joins from Kirkland & Ellis LLP, represents private equity sponsors, private credit funds, financial institutions, and public and private companies in complex financing transactions. His practice focuses on leveraged finance, acquisition financings, private credit transactions, and special situations matters, with experience spanning the energy, infrastructure, technology, manufacturing, health care, hospitality, and life sciences sectors.

"Greenberg Traurig's commitment to Texas runs deep, and our continued growth in the state reflects a deliberate focus on bringing in top-tier talent in areas of strategic importance to our clients," Executive Chairman Richard A. Rosenbaum said. "Shan's sophisticated finance practice and broad transactional experience make him an excellent addition to our Texas platform and our global capabilities."

Over the past decade, Khan has advised on transactions and financings with an aggregate value of more than $75 billion, ranging from middle-market financings to multibillion-dollar corporate transactions. His broad experience across the capital structure includes traditional lending, private credit, restructuring-related financings, and innovative solutions for companies navigating growth, acquisitions, and changing market conditions.

"Our clients are looking for counsel who can navigate increasingly complicated financing and transactional challenges," Global Finance Practice Co-Chair Arleen A. Nand said. "In addition to his impressive credentials and transactional experience, Shan is a highly collaborative lawyer whose practice complements many of our existing strengths. His versatile skill set will broaden the services we provide across the market, and we look forward to working closely with him as we continue to deepen our syndicated finance capabilities."

For Khan, it was Greenberg Traurig's entrepreneurial platform and continued investment in its finance capabilities that drew him to the firm.

"I am impressed by the firm's culture of collaboration, the strength of its finance platform, and the opportunities to work across practices and offices. I am excited to join the team and help clients navigate an increasingly dynamic financing market," Khan said.

Khan earned his J.D. from Columbia Law School, his A.M. in Near Eastern Languages and Civilizations from Harvard University, and his B.A. from The University of Texas at Austin. He is admitted to practice in Texas.

About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.

SOURCE Greenberg Traurig, LLP

Share this article

NEW YORK, Sept. 21, 2026 /PRNewswire/ -- Rutika Mehta, MD, MPH, a nationally recognized gastrointestinal (GI) medical oncologist, has joined NYU Langone Health's Perlmutter Cancer Center as director of upper GI medical oncology, further expanding the center's clinical and research programs for patients with upper GI cancers, including cancers of the esophagus and stomach.

Dr. Mehta is widely recognized for building multidisciplinary care programs and innovative clinical trials for upper GI cancers. Her research focuses on personalizing cancer treatment through molecular profiling, or detailed testing of a tumor's biology, and blood tests such as circulating tumor DNA tests, helping guide patients to the therapies most likely to benefit them.

Her arrival marks an important step in the continued growth of Perlmutter Cancer Center's Gastrointestinal Cancer Center, which brings together specialists in medical oncology, surgery, radiation oncology, gastroenterology, pathology, radiology, nutrition, and supportive care to deliver coordinated, personalized treatment. In her new role, Dr. Mehta will work closely with Noah A. Cohen, MD, section chief of complex GI surgical oncology, to further strengthen multidisciplinary care and expand clinical research opportunities.

"Dr. Mehta is an outstanding addition to Perlmutter Cancer Center at an important time in the growth of our GI Cancer Center," said Manuel Hidalgo Medina, MD, co-director of the GI Cancer Center. "Her expertise in upper GI cancers, commitment to multidisciplinary care, and extensive experience developing clinical trials will strengthen our ability to provide patients with access to innovative treatments while advancing research to improve outcomes."

Dr. Mehta treats patients with a wide range of GI cancers, specializing in cancers of the esophagus, stomach, and gastroesophageal junction—where the esophagus meets the stomach. Because these cancers often require a complex combination of treatments, she emphasizes a team-based approach that tailors care to each patient's needs and goals.

"Patients with esophageal and gastric cancers need a team that brings together the best science, the right expertise, and a clear understanding of what matters most to them," said Dr. Mehta. "I am excited to join NYU Langone and build on the growth of the GI Cancer Center by expanding personalized, biomarker-driven care and access to clinical trials, while ensuring that patients and their families feel informed and supported throughout their care."

At Perlmutter Cancer Center, Dr. Mehta will continue to expand the clinical trials available to patients with upper GI cancers, including investigator-initiated studies and trials evaluating new targeted and biomarker-driven therapies. She also serves on the National Cancer Institute's Upper GI Task Force, which helps shape national clinical research strategies for upper GI cancers.

About Dr. Mehta

Dr. Mehta joined NYU Langone from Weill Cornell Medicine, where she established an Upper GI Working Group to advance clinical and research collaboration. Previously, at Moffitt Cancer Center in Tampa, Florida, she helped build its Upper GI Malignancies Program and developed a robust clinical trials portfolio that gave patients access to new treatment options.

Her research has included clinical trials evaluating targeted therapies, immunotherapies, antibody-drug conjugates, and cellular therapies for GI cancers. She has particular expertise in HER2-positive gastroesophageal cancers and participated in the clinical development of zanidatamab, a HER2-targeted therapy. Her work also explores circulating tumor DNA and comprehensive molecular profiling to better understand treatment response, recurrence, and resistance.

In addition to her clinical and research leadership, Dr. Mehta is active in patient education and advocacy. She works closely with patient advocacy organizations, including Debbie's Dream Foundation and Hope for Stomach Cancer, participating in patient support groups, educational programs, and community events focused on GI cancers.

About NYU Langone Health

NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked NYU Langone No. 1 out of 118 comprehensive academic medical centers across the nation four years in a row, and it continues to have the most No. 1– and top 10–ranked specialties among medical centers in the United States, according to U.S. News & World Report. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 330 outpatient locations in the New York City area and Florida. The system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise.

Media Inquiries:

Lacy Scarmana

Phone: 332-215-3613

[email protected]

SOURCE NYU Langone Health

Share this article

SWCA Launches Regulatory Radar to Help Project Teams Anticipate Environmental Regulatory Change

PHOENIX, Sept. 21, 2026 /PRNewswire/ -- SWCA Environmental Consultants has launched SWCA's Regulatory Radar, a subscription-based regulatory intelligence platform that helps project teams anticipate and adapt to environmental regulatory changes before they affect budgets, reviews, permitting timelines and compliance obligations.

The regulatory environment for infrastructure, energy and development projects is moving quickly, leaving many teams to track dense policy changes while also managing active projects. Regulatory Radar helps organizations understand what changed, why it matters and what actions they should consider before a regulatory shift appears as a surprise in a comment letter, permit condition, inspection finding or project delay.

"Regulatory changes can create uncertainty for organizations responsible for complex projects," said Infrastructure Policy and Permitting Strategy Director Ross Pilotte at SWCA. "Regulatory Radar helps teams move from reaction to readiness by connecting policy developments with the practical context they need to make better project decisions."

Powered by SWCA's regulatory and technical leaders, Regulatory Radar combines policy insight with real-world experience across permitting, environmental review, compliance requirements and project delivery. Each insight includes the SWCA Lens, where SWCA advisors explain how a regulatory development may play out in practice, what they are seeing across projects and which issues may deserve closer attention.

Unlike industry newsletters that summarize what changed or legal alerts that explain what a rule requires, Regulatory Radar connects regulatory developments to the operational decisions clients face every day. It brings the value of sitting across the table from an SWCA advisor and asking, "What could this mean for my project?"

Regulatory Radar currently supports audiences focused on power and energy, infrastructure and construction compliance. Subscribers receive portal access and targeted alerts when regulatory developments may affect inspections, permits, schedules, budgets or compliance obligations. In a world of noise, Regulatory Radar provides the steady guidance project teams can use to navigate change with confidence.

Subscriptions are available for students, individuals and enterprise accounts, giving subscribers access to timely regulatory insights and project-centered guidance as new developments take shape.

About SWCA

Founded in 1981, SWCA is a 100% employee-owned environmental and management consulting firm. With a mission to be the best workplace and industry leader in sustainability, we combine scientific expertise and in-depth knowledge of the industries we serve to tackle global environmental challenges. Our experts deliver comprehensive solutions in environmental planning and permitting, cultural resources management, biological and ecological services, water resources management, resilience services, air quality, and engineering. Sound Science. Creative Solutions. www.swca.com.

Media Contact

Jara Sturdivant-Wilson

SWCA Environmental Consultants

Ph: (402) 257-1480

[email protected]

SOURCE SWCA Environmental Consultants

Share this article

Knight to Build on the Global Studio Foundation Established by Jean Venneman, Who Will Retire After More Than 30 Years in Gaming

LAS VEGAS, Sept. 21, 2026 /PRNewswire/ -- IGT announced today that, Jamie Knight will assume the role of Chief Studios Officer on Jan. 1, 2027, succeeding Jean Venneman, who will retire at the end of 2026 following more than 30 years in gaming. Knight will build on the strong foundation established under Venneman's leadership and lead IGT's continued studio investments, driving innovation across game design, content development and studio operations.

Knight brings two decades of experience across the industry's largest suppliers, with deep expertise in translating creative vision into player-favorite content. Having begun her career as a creative, she understands the collaborative process required to transform original concepts into successful products, a perspective that will inform her leadership of studio operations.

Jean Venneman, who will retire on December 31, 2026, began her career at IGT in the early 1990s and went on to hold senior leadership roles across product development, licensing, technology and operations before rejoining IGT in 2024. Since returning, she has rebuilt the company's global studio operations from the ground up. Under her leadership, she assembled and empowered a world-class studio team with more than 1,200 employees, established shared best practices across studio cultures and created the operational and creative foundation that positions IGT and Everi for accelerated growth.

"Jean's leadership created the foundation for this next phase of growth," said Hector Fernandez, IGT CEO. "She brought together talented teams, strengthened how our studios operate and raised the bar for creative and operational excellence. We are deeply grateful for everything she has contributed to our organization and our industry. Jamie's combination of creative instinct, studio leadership and focus on innovation in design and math will build on that momentum and unlock new possibilities across our combined studio organization."

As Chief Studios Officer, Knight will establish clear priorities for studio teams, drive innovation in game mechanics and mathematical modeling, and create an environment where creative talent can do exceptional work. Her vision centers on delivering the most dynamic and engaging content that meets the evolving demands of players and operators globally.

"I'm energized to lead our studio teams and build on the strong foundation in place," said Jamie Knight, incoming Chief Studios Officer. "Together with our talented teams across IGT and Everi, we'll push the boundaries of what's possible in game design, content strategy, and math innovation to deliver world-class experiences on the floor."

"Returning to this organization and helping strengthen our global studio organization has been a meaningful way to close my career," said Jean Venneman, Chief Studios Officer. "I am incredibly proud of our studio teams and the foundation we have created. I am confident Jamie will carry that momentum forward and help unlock the next phase of our growth."

For more information, follow IGT on Facebook and LinkedIn or watch IGT videos on YouTube.

About IGT

IGT is a leading global provider of gaming, digital and financial technology solutions, formed through the combination of International Game Technology PLC's Gaming & Digital Business and Everi Holdings Inc. IGT and Everi's offering spans gaming machines, game content and systems, iGaming, sports betting, cash access, loyalty and player engagement solutions, enabling it to deliver integrated, customer-centric experiences across land-based and digital environments. Organized into Gaming, Digital and FinTech business units, the organization drives innovation, efficiency and value for casino, digital and hospitality operators worldwide. The company is headquartered in Las Vegas.

Contact:

Phil O'Shaughnessy, Global Communications

Toll free in U.S./Canada +1 (844) IGT-7452

Outside U.S./Canada +1 (775) 448-0257

© 2026 IGT

The trademarks and/or service marks used herein are either trademarks or registered trademarks of IGT, its affiliates or its licensors.

SOURCE IGT

Share this article